论文部分内容阅读
目的探讨次级淋巴组织趋化因子(secondarylymphoidtissuechemokine,SLC)免疫基因转染胃癌细胞瘤苗免疫小鼠后获得的脾淋巴细胞后治疗经同一免疫基因修饰瘤苗转染的小鼠胃癌的可行性和疗效。方法用200PFU/细胞滴度的重组腺病毒载体(pVAX1)将人SLC基因转染小鼠胃癌SGC-7901细胞株,经80mg/L丝裂霉素(MMC)处理制备成胃癌细胞瘤苗,免疫同系小鼠后分离其脾淋巴细胞,转染SLC基因(腺病毒载体滴度200PFU/细胞)后注射入直径1cm的小鼠胃癌淋巴结转移模型瘤体内,观察抗瘤效果。结果转SLC基因瘤苗治疗组小鼠瘤体增加值最小(0.08±0.05)cm3,与各对照组比差异有显著性[转染SLC基因,未转染SLC和生理盐水注射组分别为(1.46±0.15)、(1.56±0.23)和(2.12±0.54)cm3,P<0.05]。结论SLC基因修饰癌瘤苗诱导小鼠产生的免疫脾淋巴细胞可能成为一种新的过继免疫治疗效应细胞及SLC基因瘤苗诱导特异性主动免疫治疗结合将有更优越的抗瘤效果和应用前景。
Objective To investigate the feasibility of using spleen lymphocytes obtained from mice immunized with secondary lymphoid tissue-stimulating factor (SLC) to immunize mice with gastric cancer cell vaccine to treat gastric cancer in mice transfected with the same immunogene modified vaccine. Efficacy. Methods Human gastric cancer cell line SGC-7901 was transfected with recombinant adenoviral vector (pVAX1) with a titer of 200 PFU / cell, and then treated with 80 mg / L mitomycin (MMC) The splenic lymphocytes were isolated from syngenic mice and transfected into SLC gene (adenovirus vector titer of 200 PFU / cell) and then injected into a 1 cm diameter mouse model of gastric cancer lymph node metastasis to observe the antitumor effect. Results The SLC gene therapy group had the smallest increase in tumor volume (0.08 ± 0.05) cm3, which was significantly different from the control group (SLC gene, SLC group and saline injection group were (1.46 ± 0.15), (1.56 ± 0.23) and (2.12 ± 0.54) cm3, respectively, P <0.05]. Conclusion SLC gene-modified cancer vaccine induced immune-producing splenic lymphocytes in mice may become a new adoptive immunotherapy effector cells and SLC gene vaccine induced specific active immunotherapy combined with superior anti-tumor effect and application prospects .